tbuckley/cabot-search huggingface dataset:
AB0943 Significance of muscle volume &amp; fatty degeneration of lumbar paraspinal muscle in spinal imbalance
Authors: Y-S Park, J Lee, J-S Park
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Spinal sagittal imbalance which is closely associated with low back pain is considered as a factor in a variety of spinal disorders. <h3>Objectives</h3> The present study was to determine the relationship between the sagittal imbalance and sarcopenia, especially cross sectional area (CSA) and fatty degeneration (FD) of muscle around the spine. <h3>Methods</h3> Overall, 165 patients are included in this study, classified by three groups according to the distance from sagittal vertical axis to posterior end of upper end plate of sacrum. 38 patients were classified as group 1 (distance ≥9cm), 50 and 53 patients as group 2 (distance 5–9cm) and group 3 (distance &lt;5cm), respectively. For measurement of CSA and FI of paraspinal muscles, five transverse T1W images of S1-S5 were obtained from PACS and measured with Adobe Photoshop 7.0®, by counting the number of pixels included in each selected muscle area. A variance analysis on average muscle surface area of those five images was done with SPSS 19.0 Windows version (SPSS Inc., Chicago, IL, USA). <h3>Results</h3> The average age of total patients was 69.1, average BMI was 22.57 and bone density was -2.34 (T-score). No significant differences were detected on ages, BMI, and bone density. Each correction coefficient of multifidus, erector spinae and psoas muscle was 0.80, 0.75 and 0.81, respectively. CSA of paraspinal muscles has significant differences between group I and III, II and III. Psoas has significant differences between all groups. FI has significant differences between all groups in multifidus and between I and III, II and III in erector spinae. But, psoas has no significance between three groups. <h3>Conclusions</h3> Authors were able to detect significant muscle atrophy in the group with severe imbalance. And degeneration of paravertebral muscle has significant increased with sagittal imbalance. Effort for preventing weakness of muscle around spine might cause influence to alignment of spine. <h3>References</h3> Fortin M, Lazáry À, Varga PP, McCall I, Battié MC. Paraspinal muscle asymmetry and fat infiltration in patients with symptomatic disc herniation. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc 2016;25:1452–9. doi:10.1007/s00586–016–4503–7. Lee SH, Park SW, Kim YB, Nam TK, Lee YS. The fatty degeneration of lumbar paraspinal muscles on computed tomography scan according to age and disc level. Spine J Off J North Am Spine Soc 2016. doi:10.1016/j.spinee.2016.08.001. <h3>Disclosure of Interest</h3> None declared
FRI0619 Comparing canakimumab and anakinra in young greek women with resistant recurring pericarditis
Authors: P Kiryttopoulos, T Michailidis, E Papchianou, M Charalampidis, P Dimitriadis, A Agorastos, T Mpektsis
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Resistant – recurring pericarditis (RRP) is often associated with autoinflammatory syndromes. Conventional therapy with glucocorticoids and colchicine is often enough unsuccessful, thus nowadays the use of anakinra in such cases is becoming common every – day practice. <h3>Objectives</h3> Our goal was to determine whether RRP was associated with gene mutations relevant with autoinflammatory diseases and then compare the effectiveness of canakimumab and anakinra. <h3>Methods</h3> We studied 18 patients with RRP (all women, from 14 to 36 years old) determing the existence of mutation from the infevers database (25 genes, from MEFV and TNFRSF1A to MVK and SLC 29A3, all related with autoinflammatory diseases). All the patients were proven positive to one of the above mutations (all heterozygous) and then treatment with anakinra (n=9, 100mg sc once daily) and canakimumab (n=9, 150mg sc q4wk) was administered. <h3>Results</h3> During the study (3 years), all anakinra patients stopped receiving per os glucocorticoids and were free of any new pericarditis episodes. 3 of them (33%) stopped any treatment after a year of anakinra therapy and none was presented with any skin reactions. On the contrary, all canakimumab patients were not able to free themselves of the glucocorticoid treatment, since at least one new episode of pericarditis to each patient was recorded. Two of them were free of pericarditis the last year of the study (though being treated with 2,5mg prednisolone per os daily). Statistically speaking, the use of IL-1R antagonist in recurrent – resistant pericarditis associated with autoinflammatory mutations was proven much more successful (p&lt;0,01) than the use of the IL-1b Mab. <h3>Conclusions</h3> Though the sample of patients (n=18) was too small in order to set us able to reach any safe conclusions, it is quite possible that anakinra may be one effective solution that can prevent the long term administration of corticoids to patients with recurrent pericarditis Canakimumab was not recorded with similar positive results. <h3>Disclosure of Interest</h3> None declared
SP0052 Building patient partnership in health care service design and delivery
Authors: H Lempp
Journal: Annals of the Rheumatic Diseases (2017)

This paper will present details of the approach to patient and public involvement in health service delivery, health service research and health care education in England. The presentation will be based upon a Logical Framework with the following key elements: inputs, processes, outputs, and outcomes/impacts. Key barrier acting to minimise the impact of building patient partnerships will be discussed, illustrated by examples from our experience in the preparatory stages for our departmental strategy to formalise close Patient Partnership for our research portfolio: (i) establish honorary contracts for patients for the academic Institution and local Hospital Trust; (ii) include patients on the interview panels to appoint project researchers (iii) build in a separate funding within the overall project budget for the costs associated with patient partnership and (iv) manage patient expectations of rapid implementation of the results of research after the completion of projects. Patient Partnership is essential and feasible to make health care service and design relevant. <h3>References</h3> Otto AK, Novielli K, Morahan PS.(2006) Implementing the logic model for measuring the value of faculty affairs activities. Acad Med. 2006 Mar;81(3):280–5. Mockford C, Staniszewska S, Grifiths F, Herron–Marx S. The impact of patient and public involvement on UK NHS health care: a systematic review. International Journal for Quality in Health Care, 2012; 24:28–38. <h3>Disclosure of Interest</h3> None declared
THU0288 Comparison of the clinical, serological, and prognostic differences among JUVENILE-, ADULT-, and late-onset lupus nephritis in korean patients: a case-control study
Authors: S-S Lee, J-H Kang, J-E Kim, K-E Lee, D-J Park
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> SLE patients present with different clinical and serological manifestations according to the age at disease onset. However, it is not known whether there is an association between disease onset age and the clinical presentation of lupus nephritis (LN). Therefore, we investigated whether LN patients could be distinguished based on the time of disease onset and, if so, whether the groups differed in their clinical, laboratory features and long-term prognosis in ethnically homogeneous Korean patients. <h3>Methods</h3> We enrolled 117 SLE patients with available clinical data at the time of renal biopsy for LN from the lupus cohort at Chonnam National University Hospital. We divided the LN patients according to the age at LN diagnosis into three groups [juvenile-onset LN (JLN), diagnosed at ≤18 years; adult-onset LN (ALN), diagnosed at 18–50 years; and late-onset LN (LLN), diagnosed at &gt;50 years] and compared the baseline demographic, clinical, histological, and relevant laboratory findings. We also compared the treatment and long-term prognosis of LN according to those three groups. <h3>Results</h3> Of the 114 LN patients, 20 (17.5%), 84 (71.8%), and 13 (11.1%) had JLN, ALN, and LLN, respectively. LLN patients were less educated than ALN and JLN patients (<i>p</i> &lt;0.001). Hypertension and diabetes mellitus at the onset of LN were more common in LLN patients than ALN or JLN patients (<i>p</i>&lt;0.001 and?<i>p</i>=0.037, respectively). Regarding the laboratory findings, LLN patients had a higher white blood cell count and lower eGFR than ALN or JLN patients (<i>p</i>&lt;0.011 and 0.002, respectively). Histologically, LLN patients had more chronicity indices and a higher chronic score (<i>p</i> =0.006, <i>p</i> =0.019, <i>p</i>&lt;0.001 and <i>p</i>&lt;0.001, respectively). Anti-Ro antibodies were found more frequently in ALN patients and less frequently in JLN patients (<i>p</i> =0.024) and lower complement levels were more common in JLN patients and less common in LLN patients (<i>p</i>&lt;0.011 and 0.002, respectively). During a mean follow-up of 76.5 months, the development of chronic kidney disease and death from any cause were higher in LLN patients than in JLN and ALN patients (<i>p</i> =0.028 and <i>p</i> =0.038, respectively). <h3>Conclusions</h3> LN patients present with different clinical and serological manifestations according to age at disease onset. Interestingly, LLN patients had more chronicity at the time of renal biopsy, and more deterioration of kidney function and death on long-term follow-up, than JLN and ALN patients. Therefore, LLN patients should be monitored and managed carefully to avoid poor outcomes. <h3>Disclosure of Interest</h3> None declared
SAT0225 Cereblon modulator CC-220 decreases naÏve and memory B cells and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients: exposure-response results from a phase 2A proof of concept study
Authors: A Gaudy, Y Ye, S Korish, D Hough, M Weiswasser, S Choi, R Furie, V Werth, P Schafer
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> CC-220 is a cereblon E3 ligase modulatory compound currently in development for the treatment of Systemic Lupus Erythematosus as well as other autoimmune conditions and multiple myeloma. As a high affinity ligand for cereblon, CC-220 administration results in significant reductions in ikaros (IKZF1) and aiolos (IKZF3), transcription factors which are genetically linked to SLE risk, and are overexpressed in the peripheral blood of SLE patients compared to healthy controls. <h3>Objectives</h3> To describe the pharmacokinetics (PK), pharmacodynamics (PD), and the PK-PD relationship of CC-220 in subjects with SLE. <h3>Methods</h3> CC-220-SLE-001 is a randomized, double-blinded, placebo-controlled, phase 2a dose escalation study to investigate the safety, PK, PD, and efficacy of CC-220 in patients with SLE. Forty-two (42) adult SLE subjects fulfilling SLE ACR criteria, having a history of SLE for ≥6 months and a baseline Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥4 were randomized to placebo or 1 of 4 escalating doses of CC-220 (0.3 mg QOD, 0.3 mg QD, 0.6/0.3 mg alternating QD, or 0.6 mg QD). <h3>Results</h3> CC-220 concentration-time profiles demonstrated dose proportionality between cohorts, with moderate accumulation in the non-alternating dose cohort. CC-220 significantly reduced total CD20+ B cells by as much as 96%, immature B cells by as much as 91.2%, switched memory B cells by as much as 81.4%, BAFFR+ B cells by as much as 67.5%, and plasmacytoid dendritic cells (pDCs) by as much as 86.5% (Day 85 median percent change from baseline). Whereas reductions in B cells were observed, CD4+ as well as CD8+ T cells increased, and the rise in T cells paralleled the observed increase in plasma cells in those subjects who received the highest dose (0.6 mg). An exposure-response analysis demonstrated decreasing B cells, pDCs and neutrophils with increased exposure to CC-220. <h3>Conclusions</h3> It was determined that 0.3 mg QD to 0.6/0.3 mg alternating QD reduced concentrations of B cells and pDC9s while avoiding neutropenia. These findings, in combination with the PK, safety, and exploratory efficacy data, support continued development of CC-220 in SLE. <h3>Disclosure of Interest</h3> A. Gaudy Shareholder of: Celgene, Employee of: Celgene, Y. Ye Shareholder of: Celgene, Employee of: Celgene, S. Korish Shareholder of: Celgene, Employee of: Celgene, D. Hough Shareholder of: Celgene, Employee of: Celgene, M. Weiswasser Shareholder of: Celgene, Employee of: Celgene, S. Choi Shareholder of: Celgene, Employee of: Celgene, R. Furie Consultant for: Celgene, V. Werth Grant/research support from: Celgene, Consultant for: Celgene, P. Schafer Shareholder of: Celgene, Employee of: Celgene
Parental Occupational Exposure to Organic Solvents and Testicular Germ Cell Tumors in their Offspring: NORD-TEST Study
Authors: Charlotte Le Cornet, Béatrice Fervers, Eero Pukkala, Tore Tynes, Maria Feychting, Johnni Hansen, Kayo Togawa, Karl-Christian Nordby, Susanne Oksbjerg Dalton, Sanni Uuksulainen, Pernilla Wiebert, Torill Woldbæk, Niels E. Skakkebæk, Ann Olsson, Joachim Schüz
Journal: Environmental Health Perspectives (2017)

Background: Testicular germ cell tumors (TGCT) were suggested to have a prenatal environmentally related origin. The potential endocrine disrupting properties of certain solvents may interfere with the male genital development in utero. Objectives: We aimed to assess the association between maternal and paternal occupational exposures to organic solvents during the prenatal period and TGCT risk in their offspring. Methods: This registry-based case control study included TGCT cases aged 14–49 y (n=8,112) diagnosed from 1978 to 2012 in Finland, Norway, and Sweden. Controls (n=26,264) were randomly selected from the central population registries and were individually matched to cases on year and country of birth. Occupational histories of parents prior to the child’s birth were extracted from the national censuses. Job codes were converted into solvent exposure using the Nordic job-Nordic Occupational Cancer Study Job-Exposure Matrix. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Results: Overall, no association was found between prenatal maternal exposure to solvents and TGCT risk. In subset analyses using only mothers for whom occupational information was available in the year of or in the year prior to the child’s birth, there was an association with maternal exposure to aromatic hydrocarbon solvents (ARHC) (OR=1.53; CI: 1.08, 2.17), driven by exposure to toluene (OR=1.67; CI: 1.02, 2.73). No association was seen for any paternal occupational exposure to solvents with the exception of exposure to perchloroethylene in Finland (OR=2.42; CI: 1.32, 4.41). Conclusions: This study suggests a modest increase in TGCT risk associated with maternal prenatal exposure to ARHC. https://doi.org/10.1289/EHP864
SP0002 Novel animal models in systemic sclerosis
Authors: X Yu
Journal: Annals of the Rheumatic Diseases (2017)

Systemic sclerosis (SSc) is a severe autoimmune disease with a considerable reduction of life expectancy. Autoimmunity, vasculopathy and fibrosis are three hallmarks of SSc, while the pathogenesis of the disease is largely unknown. Animal models of SSc provide an excellent tool to for exploring the disease pathogenesis of the disease. Aiming to provide a concise and curate updates in the field of animal models of SSc, this lecture will concentrate on emerging novel animal models and highlight new development and their impact on understanding pathogenesis of SSc. <h3>Disclosure of Interest</h3> None declared
SAT0476 Demographic, clinical, and laboratory characteristics of elderly onset psoriatic arthritis
Authors: S Kobak, M Orman
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Psoriatic arthritis (PsA) is a chronic inflamatory disease characterized with axial and peripheral joints involvement. It is rarely affects patients older than 65 years old. <h3>Objectives</h3> The purpose of this study is to compare and evaluate the demographic, clinical and laboratory features of elderly-onset psoriatic arthritis (EOPsA) and young-onset (YOPsA) patients. <h3>Methods</h3> One hundred and eighty patients diagnosed with PsA according to CASPAR criteria and followed-up in single center were included in this study. The patients with initial symptoms started after age 65 were accepted as EOPsA. Demographic, clinical, and laboratory data and the medications which the patients recieved were recorded and retrospectively evaluated. <h3>Results</h3> Nineteen (10.5%)of 180 patients were diagnosed as EOPsA, and 161 (89.5%) patients were evaluated as YOPsA. Mean patient age was 42.1years for YOPsA group and 68.3years for elderly onset group. Mean duration of disease was 5.6 years for early onset group and 1.3 years for elderly onset group (p=0.001). Fourteen (73.3%) of 19 EOPsA patients were female and 5 of them were male. Higher rates of fatique, pain scores, comorbid diseases and acute phase reactants were detected in EOPsA patients comparing to YOPsA (p=0.000, p=0.000, p=0.001 and p=0.001 respectively). YOPsA patients have more dactilitis, nail involvement, elevated PASI scores, and smoking habitus when compared with EOPsA patients (p=0.019, p=0.03, p=0.005, p=0.004 respectively). In terms of the treatment options chosen, there was no significant difference in the use of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CS), methotrexate (MTX), and sulfasalazine (SSL), but there was a more frequent use of anti-tumor necrosis factor -alpha in YOPsA group. <h3>Conclusions</h3> Herein we showed that YOPsA and EOPsA patients may have different demographic, clinical, and laboratory features. EOPsA patients are characterized with higher rates of fatique, pain scores, comorbid diseases, and acute phase reactants and less dactilitis, nail involvement and anti-TNF-alpha usage. <h3>Disclosure of Interest</h3> None declared
SAT0562 Chikungunya fever in patients with prior rheumatic diseases: is it more severe?
Authors: AT Dantas, MS Luna, PR Santos, CA Andrade, CDL Marques, A Ranzolin, NG Cavalcanti, RS Gonçalves, LF Rocha Junior, HD Lima, PR Melo, LD Valadares, CA da Fonte, MLD Valadares, E Freire, AKG Melo, MM Medeiros, MC Bezerra, VB Marques, RA Océa, AL Duarte
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Chikungunya fever (CF) is an infectious disease caused by a RNA virus and its transmission occurs by the inoculation of the virus by the female bite of <i>Aedes aegypti</i> mosquito. In Brazil, where the vetor is endemic, the virus rapidly disseminated and there was an epidemic, specially in the Northeast region of the country with 263.980 notified cases in 2016. It is known that CF may have a chronic course with articular symptons, however there is not consistent data in the medical literature on CF evolution in patients with prior rheumatic diseases. <h3>Objectives</h3> To assess whether there is any difference in the characteristics of articular manifestations of CF in patients with prior inflammatory rheumatic diseases (IRD), non-inflammatory rheumatic diseases (NIRD) and controls (patients with no diagnosed prior rheumatic diseases). <h3>Methods</h3> Cross-sectional study using a database from CHIKBRASIL cohort. Patients enrolled had clinical and epidemiological characteristics of CF and were classified in three groups: IRD (rheumatoid arthritis, axial spondyloarthritis and systemic lupus erythematosus), NIRD (fibromyalgia and osteoarthritis) and controls (no prior rheumatic diseases). <h3>Results</h3> A total of 150 patients were enrolled. There were 55 patients with IRD, 40 patients with NIRD and 55 controls, paired by age and sex. There were no differences in acute phase symptoms in the groups. There a was more frequent occurrence of arthritis in patients with IRD compared to NIRD (p=0.001) and to controls (p=0.002). In 89.1% of the patients with IRD there was an underlying disease exacerbation and 74% described an expressive worsening of symptoms compared to the period prior to infection. Patients with IRD had an increase in the current dose of corticosteroids (median 10mg, IQR 10–20) compared to previous dose used (median 6mg, IQR 5–10) after the onset of CF (p=0.0007). Importantly, there was more methotrexate prescription (23.5%) in IRD group, compared to NIRD group (0, p-0.001) and to controls (3.7%, p=0.003). <h3>Conclusions</h3> Patients with IRD and CF presented significantly more arthritis compared to NIRD or to controls. CF seems to induce underlying rheumatologic disease exacerbation in patients with inflammatory disease and a more aggressive therapeutic approach might be necessary in this group of patients. <h3>Disclosure of Interest</h3> None declared
SAT0125 Tenosynovitis in rheumatoid arthritis: prevalence and determinants of tenosynovitis detected in the sonar-ultrasound examination in the scqm cohort
Authors: R Micheroli, A Scherrer, L Brulhardt, H Ziswiler, P Zufferey, B Möller, A Ciurea, G Tamborrini
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Tenosynovitis is one of the common features of rheumatoid arthritis (RA). The diagnosis of tenosynovitis is frequently made clinically but for the detection of tenosynovitis, ultrasound (US) is more sensitive. US and MRI detected tenosynovitis is a predictor for unstable remission and erosive progression in RA<sup>.</sup> <h3>Objectives</h3> The aim of this study was to assess the prevalence and determinants of TS detected in the SONAR (Swiss Sonography Group in Arthritis and Rheumatism) examinations in patients with Rheumatoid Arthritis in the SCQM Cohort. <h3>Methods</h3> The SONAR ultrasound examination consists of a semi-quantitative score employing both multiplanar gray scale (B-mode) and Doppler-mode (PwD) and a TS composite score (grade 0–3). Pathologic TS was defined as TS grade 2–3. Characteristics of patients with and without TS are shown using standard descriptive methods. In a longitudinal sub-group the change in TS from no TS to pathologic TS or vice versa and DAS28 over time was categorized as "worse" (ΔDAS28 ≥2.1), "same" and "better" (ΔDAS28 ≤-2.1) and the correlation between change DAS28 and in tenosynovitis was evaluated. <h3>Results</h3> 941 RA patients with TS score were available. 20% of included patients showed signs of TS. The presence of TS was associated with male gender and higher values of disease activity and physical function disability. Furthermore, 15% of patients in DAS28 Remission had sonographic TS. TS was less frequently observed in patients on biologic therapies (Table 1). The longitiudinal sub-group consisted of 348 patients. The correlation between change in DAS28 and change in TS was poor (polychoric correlation 0.28 [0.14, 0.43]). <h3>Conclusions</h3> In the SCQM RA cohort TS is associated with male gender and an overall higher disease activity. One should actively look for TS even in RA patients in DAS28 remission. <h3>Disclosure of Interest</h3> None declared